Tin tức & Cập nhật

Hypophosphatemia events more frequent with ferric carboxymaltose vs ferric derisomaltose
Hypophosphatemia events more frequent with ferric carboxymaltose vs ferric derisomaltose
16 Sep 2022
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
15 Sep 2022 bởiRoshini Claire Anthony

First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.

First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
15 Sep 2022
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
14 Sep 2022 bởiRoshini Claire Anthony

In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.

Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
14 Sep 2022
MRNA booster shot durably bolsters defenses against severe COVID-19
MRNA booster shot durably bolsters defenses against severe COVID-19
14 Sep 2022